Poseida Therapeutics' P-BCMA-ALLO1 receives US FDA RMAT designation to treat ...
Poseida Therapeutics announced FDA's RMAT designation for P-BCMA-ALLO1, an allogeneic CAR-T therapy in phase 1/1b for relapsed/refractory multiple myeloma, based on early promising data. The designation includes Fast Track and Breakthrough Therapy benefits, facilitating early FDA interactions. Poseida plans to report new clinical data at the 21st International Myeloma Society Annual Meeting in 2024.
Related Clinical Trials
Reference News
Poseida Therapeutics announced FDA's RMAT designation for P-BCMA-ALLO1, an allogeneic CAR-T therapy in phase 1/1b for relapsed/refractory multiple myeloma, based on early promising data. The designation includes Fast Track and Breakthrough Therapy benefits, facilitating early FDA interactions. Poseida plans to report new clinical data at the 21st International Myeloma Society Annual Meeting in 2024.
Poseida Therapeutics' P-BCMA-ALLO1, an allogeneic CAR-T therapy, received FDA's RMAT designation for treating relapsed/refractory multiple myeloma. The therapy, rich in stem cell memory T-cells, targets BCMA and is in a phase 1/1b trial. Early data showed an 82% overall objective response rate and was well-tolerated, with no cases of graft versus host disease. Poseida plans to present updated results at the 21st International Myeloma Society Annual Meeting in 2024.